{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-003316","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.526994+00:00","generated_at":"2026-05-16T08:36:55.660451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanara MedTech reports preliminary FY 2025 revenue ~$103M, guides FY 2026 revenue $116M-$121M","bullets":["Q4 2025 net revenue expected $27.2M-$27.7M, up 3-5% YoY; excluding $1.8M BIASURGE sales in Q4'24, growth 11-13%.","FY 2025 net revenue expected $102.7M-$103.2M, ~19% YoY growth; excluding $1.8M BIASURGE, growth 21-22%.","FY 2026 guidance: net revenue $116M-$121M, growth 13-17% from 2025 midpoint.","Cash $16.6M, long-term debt $46.0M at Dec 31, 2025 (vs $15.9M cash, $30.7M debt a year earlier).","BIASURGE receives Vizient Innovative Technology contract; OsStic launch planned Q1 2027 pending FDA clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-003316","json":"https://secwatch.observer/filing/0001493152-26-003316.json","markdown":"https://secwatch.observer/filing/0001493152-26-003316.md","text":"https://secwatch.observer/filing/0001493152-26-003316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315226003316/0001493152-26-003316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315226003316/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:36:55.660451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}